Neidio i’r brif dudalen lywio Neidio i chwilio Neidio i’r prif gynnwys

A randomised controlled trial of a digital intervention (Renewed) to support symptom management, wellbeing and quality of life in cancer survivors

  • Paul Little
  • , Katherine Bradbury
  • , Beth Stuart
  • , Jane Barnett
  • , Adele Krusche
  • , Mary Steele
  • , Elena Heber
  • , Steph Easton
  • , Kirsten A. Smith
  • , Joanna Slodowska-Barabasz
  • , Liz Payne
  • , Teresa Corbett
  • , Laura Wilde
  • , Guiqong LIly Yao
  • , Sebastien Pollet
  • , Jazzine Smith
  • , Judith Joseph
  • , Megan Lawrence
  • , Dankmar Böhning
  • , Tara Cheetham-Blake
  • Diana Eccles, Claire Foster, Adam William Alfred Geraghty, Geraldine Leydon, Andre Matthias Müller, Richard D. Neal, Richard Osborne, Shanaya Rathod, Alison Richardson, Chloe Grimmett, Geoffrey Sharman, Roger Bacon, Lesley Turner, RIchard Stephens, Kirsty Rogers, James Raftery, Shihua Zhu , Karmpaul Singh, Frances Webley, Gareth Griffiths, Jaqui Nutall, Trudie Chalder, Clare Wilkinson, Ella Watson, Lucy Yardley
  • University of Southampton
  • Department of Sport and Health Sciences, Oxford Brookes University, Oxford
  • National University of Singapore
  • College of Life and Environmental Sciences, University of Exeter, Penryn Campus, Penryn, 9 TR10 9EZ, UK.
  • Dorset Cancer Centre, Poole, UK.
  • Southern Health NHS Foundation Trust, Southampton, UK.
  • Public & Patient Inclusion
  • University of Calgary
  • Kings College London
  • University of Bristol

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

136 Wedi eu Llwytho i Lawr (Pure)

Crynodeb

Background
Many cancer survivors following primary treatment have prolonged poor quality of life.
Aim. To determine the effectiveness of a bespoke digital intervention to support cancer survivors.
Design. Pragmatic parallel open randomised trial.
Setting. UK general practices.
Methods. People having finished primary treatment (<= 10 years previously) for colo-rectal, breast or prostate cancers, with European-Organization-for-Research-and-Treatment-of-Cancer QLQ-C30 score <85, were randomised by online software to: 1)detailed ‘generic’ digital NHS support (‘LiveWell’;n=906), 2) a bespoke complex digital intervention (‘Renewed’;n=903) addressing symptom management, physical activity, diet, weight loss, distress, or 3) ‘Renewed-with-support’ (n=903): ‘Renewed’ with additional brief email and telephone support.
Results. Mixed linear regression provided estimates of the differences between each intervention group and generic advice: at 6 months (primary time point: n’s respectively 806;749;705) all groups improved, with no significant between-group differences for EORTC QLQ-C30, but global health improved more in both intervention groups. By 12 months there were: small improvements in EORTC QLQ-C30 for Renewed-with-support (versus generic advice: 1.42, 95% CIs 0.33-2.51); both groups improved global health (12 months: renewed: 3.06, 1.39-4.74; renewed-with-support: 2.78, 1.08-4.48), dyspnoea, constipation, and enablement, and lower NHS costs (generic advice £265: in comparison respectively £141 (153-128) and £77 (90-65) lower); and for Renewed-with-support improvement in several other symptom subscales. No harms were identified.
Conclusion. Cancer survivors quality of life improved with detailed generic online support. Robustly developed bespoke digital support provides limited additional short term benefit, but additional longer term improvement in global health enablement and symptom management, with substantially lower NHS costs.
Iaith wreiddiolSaesneg
CyfnodolynBritish Journal of General Practice
Dyddiad ar-lein cynnar20 Rhag 2023
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsE-gyhoeddi cyn argraffu - 20 Rhag 2023

NDC y CU

Mae’r allbwn hwn yn cyfrannu at y Nod(au) Datblygu Cynaliadwy canlynol

  1. NDC 3 - Iechyd a Llesiant Da
    NDC 3 Iechyd a Llesiant Da

Ôl bys

Gweld gwybodaeth am bynciau ymchwil 'A randomised controlled trial of a digital intervention (Renewed) to support symptom management, wellbeing and quality of life in cancer survivors'. Gyda’i gilydd, maen nhw’n ffurfio ôl bys unigryw.

Dyfynnu hyn